基于入院生物标志物预测COVID-19结局:一项英国前瞻性队列研究
DISCOVER研究前瞻性纳入英国一家医院连续收治的187例确诊或临床影像学疑似COVID-19患者,在入院血样中检测IL-6、suPAR、KL-6、肌钙蛋白、铁蛋白、LDH、BNP、降钙素原及常规标志物,以无创通气、ICU入住或死亡复合结局为终点。IL-6(AUC 0.77)和suPAR(AUC 0.81)表现最佳,但NEWS2评分(AUC 0.70)和年龄(AUC 0.70)等简单临床特征预测价值接近。CRP(AUC 0.69)、淋巴细胞计数(AUC 0.62)等常规标志物未能预测主要结局。作者认为入院血生物标志物预测价值中等,进一步研究应关注这些标志物对常规诊疗的附加价值。
要点
- 在187例入院COVID-19患者中,suPAR预测复合结局(无创通气、ICU入住或死亡)的AUC为0.81(95%CI 0.72-0.88),IL-6的AUC为0.77(95%CI 0.65-0.88),表现最佳。
- 简单临床特征NEWS2评分(AUC 0.70,95%CI 0.60-0.79)和年龄(AUC 0.70,95%CI 0.62-0.77)的预测价值接近IL-6和suPAR,且优于多数生物标志物。
- CRP(AUC 0.69,95%CI 0.59-0.78)和淋巴细胞计数(AUC 0.62,95%CI 0.53-0.72)等常规标志物未能预测主要结局。
- 作者认为入院血生物标志物对COVID-19结局仅中等预测价值,进一步研究应聚焦IL-6和suPAR对常规诊疗的附加价值。
适用人群与场景
- 英国一家医院连续收治的成年患者,确诊或临床影像学疑似COVID-19,签署知情同意后纳入前瞻性队列。
诊断标准与关键阈值
- 复合主要结局:无创通气、ICU入住或死亡。
- 使用NEWS2评分、CURB-65评分和初始胸片影像学严重程度评分作为临床比较指标。
研究设计与关键结果
- 前瞻性队列研究,纳入187例入院COVID-19患者,分析28天结局。
- IL-6预测复合结局的AUC为0.77(95%CI 0.65-0.88),suPAR的AUC为0.81(95%CI 0.72-0.88),表现最佳。
- NEWS2评分AUC为0.70(95%CI 0.60-0.79),年龄AUC为0.70(95%CI 0.62-0.77),预测价值接近IL-6和suPAR。
- CRP(AUC 0.69,95%CI 0.59-0.78)、淋巴细胞计数(AUC 0.62,95%CI 0.53-0.72)及其他常规标志物未能预测主要结局。
- 作者结论:入院血生物标志物对COVID-19结局仅中等预测价值,年龄和NEWS2评分优于多数生物标志物,IL-6和suPAR表现最佳,进一步研究应关注这些标志物对常规诊疗的附加价值。
证据类型、等级与局限
- 前瞻性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为入院血生物标志物对COVID-19结局仅中等预测价值,简单临床特征如年龄和NEWS2评分表现不劣于多数生物标志物,进一步研究应关注IL-6和suPAR对常规诊疗的附加价值。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: COVID-19 has an unpredictable clinical course, so prognostic biomarkers would be invaluable when triaging patients on admission to hospital. Many biomarkers have been suggested using large observational datasets but sample timing is crucial to ensure prognostic relevance. The DISCOVER study prospectively recruited patients with COVID-19 admitted to a UK hospital and analysed a panel of putative prognostic biomarkers on the admission blood sample to identify markers of poor outcome.
METHODS: Consecutive patients admitted to hospital with proven or clinicoradiological suspected COVID-19 were consented. Admission bloods were extracted from the clinical laboratory. A panel of biomarkers (interleukin-6 (IL-6), soluble urokinase plasminogen activator receptor (suPAR), Krebs von den Lungen 6, troponin, ferritin, lactate dehydrogenase, B-type natriuretic peptide, procalcitonin) were performed in addition to routinely performed markers (C reactive protein (CRP), neutrophils, lymphocytes, neutrophil:lymphocyte ratio). Age, National Early Warning Score (NEWS2), CURB-65 and radiographic severity score on initial chest radiograph were included as comparators. All biomarkers were tested in logistic regression against a composite outcome of non-invasive ventilation, intensive care admission or death, with area under the curve (AUC) (figures calculated).
RESULTS: 187 patients had 28-day outcomes at the time of analysis. CRP (AUC: 0.69, 95% CI: 0.59 to 0.78), lymphocyte count (AUC: 0.62, 95% CI: 0.53 to 0.72) and other routine markers did not predict the primary outcome. IL-6 (AUC: 0.77, 0.65 to 0.88) and suPAR (AUC: 0.81, 0.72 to 0.88) showed some promise, but simple clinical features alone such as NEWS2 score (AUC: 0.70, 0.60 to 0.79) or age (AUC: 0.70, 0.62 to 0.77) performed nearly as well.
DISCUSSION: Admission blood biomarkers have only moderate predictive value for predicting COVID-19 outcomes, while simple clinical features such as age and NEWS2 score outperform many biomarkers. IL-6 and suPAR had the best performance, and further studies should focus on the additive value of these biomarkers to routine care.
参考来源
- Arnold DT, Attwood M, Barratt S, et al. Predicting outcomes of COVID-19 from admission biomarkers: a prospective UK cohort study. Emerg Med J. 2021. PMID: 34021028. doi:10.1136/emermed-2020-210380
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。